Oryzon Genomics Sa Is A Clinical Stage Biopharmaceutical Company Based In Spainspecializing In Epigenetics Based Therapeutics For Oncology And Central Nervous Systemcnsdisordersthe Company Is Listed On The Spanish Stock Exchange And Focuses On Personalized Medicineadvancing Drug Candidates Through Phase Ii Trials Before Exploring Partnerships For Late Stage Development Oryzon S Core Areas Include Oncologytargeting Cancers Such As Acute Myeloid Leukemiaamland Small Cell Lung Cancersclc As Well As Cns Disorders Like Alzheimerae S Disease And Cognitive Impairment Related To Multiple Sclerosiskey Products In Development Include Iadademstatan Lsd1 Inhibitor In Phase Ii Trials For Aml And Sclcand Vafidemstata Cns Optimized Lsd1 Inhibitor Undergoing Multiple Phase Ii Trials For Various Cns Conditionsthe Company Also Has A Preclinical Epigenetic Modulatorory 3001Aimed At Non Oncological Diseases With A Commitment To Addressing Unmet Medical Needsoryzon Is Recognized As A Leader In Epigenetic Therapeutics In Europethe Company Maintains A Focus On Transparency With Its Stakeholdersincluding Investors And Research Collaborators
No conferences found for this company.
| Company Name | Oryzon Genomics United States |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
